Lindsay Piet
Medical · Maitland, FLNPI 1922485473
Payments from drug & device makers
Across 244 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Photonicare Inc$1K
- AbbVie$1K
- Amgen$537
- GSK$409
- Novo Nordisk$308
- Axsome Therapeutics, Inc.$253
- plus $2K from 38 others
What the payments were for
- Speaking & faculty fees$170%
- Food & beverage$4,79579%
- Other$1,25021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OtoSight Middle Ear Scope$1,250
- Repatha$260
- TRELEGY ELLIPTA$232
- DEXCOM G6 TRANSMITTER$138
- KISUNLA$125
- Symbravo$123
- GEMTESA$112
- VOQUEZNA$111
How this compares
$6,062 in reported general payments places this provider in the 85th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $22,046 |
| JardianceEmpagliflozin | 14 | $20,766 |
| EliquisApixaban | 11 | $18,906 |
| OzempicSemaglutide | 13 | $12,614 |
| Novolin NInsulin Nph Human Isophane | 11 | $1,566 |
| Rosuvastatin Calcium | 132 | $970 |
| Ezetimibe | 35 | $619 |
| Atorvastatin Calcium | 67 | $566 |
| Gabapentin | 37 | $525 |
| Tizanidine Hcl | 33 | $523 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $471 |
| Hydroxyzine Hcl | 13 | $467 |
| Levothyroxine Sodium | 34 | $419 |
| Tamsulosin Hcl | 34 | $404 |
| Amlodipine Besylate | 55 | $369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $206 | $22,04621 claims |
| Boehringer IngelheimJardiance | $27 | $20,76614 claims |
| PfizerEliquis | $65 | $18,90611 claims |
| Novo NordiskOzempic | $308 | $12,61413 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $12325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,031 medical providers in Florida.
Other medical in Maitland
- Demittre SorensonMaitland$23K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.